Resmed Inc. RMD

Revenue Intelligence Report • 47 quarters of SEC filing data • Updated 2026-03-06

Resmed Inc. demonstrates a robust revenue model driven primarily by strategic investments in R&D and SG&A, with elasticities of 0.22% and 1.47%, respectively, indicating a strong return on investment for these expenditures. The company has consistently delivered solid performance, evidenced by a recent quarterly revenue of $1.423 billion, which reflects a 4.9% variance from predictions, showcasing a reliable forecasting capability with a 2.0% MAPE. Looking ahead, the fiscal year forecast projects a revenue of $6 billion, representing a 10.1% year-over-year growth, positioning Resmed favorably for continued expansion in the healthcare market.

Next FY Revenue

$5.87B

+10.1% YoY

R&D Elasticity

0.22x

SG&A Elasticity

1.47x

Model Accuracy

2.0% MAPE

Holdout validation: The model predicted $1B vs the actual $1B — an error of 4.9%.

Revenue Forecast

Quarterly Detail

Quarter	Model Forecast	Actual	95% Range	YoY Growth	Status
Q4 2025	$1B	$1B	$1B – $1B	+10.6%	✗ Outside range
Q2 2026	$1B		$1B – $2B	+9.2%
Q3 2026	$1B		$1B – $2B	+11.9%
Q4 2026	$1B		$1B – $2B	+11.6%
Q1 2027	$2B		$1B – $2B	+8.0%

How Spending Drives Revenue

Reading this chart: Each line shows the cumulative elasticity — how a 1% increase in spending translates to revenue growth over subsequent quarters. The effect builds over 4-5 quarters as investments compound.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch